BR0111199A - Compostos heterocìclicos - Google Patents

Compostos heterocìclicos

Info

Publication number
BR0111199A
BR0111199A BR0111199-0A BR0111199A BR0111199A BR 0111199 A BR0111199 A BR 0111199A BR 0111199 A BR0111199 A BR 0111199A BR 0111199 A BR0111199 A BR 0111199A
Authority
BR
Brazil
Prior art keywords
lowering effect
effect
formula
heterocyclic compounds
blood
Prior art date
Application number
BR0111199-0A
Other languages
English (en)
Inventor
Kenji Kuwabara
Tomiyoshi Aoki
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Publication of BR0111199A publication Critical patent/BR0111199A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

"COMPOSTOS HETEROCìCLICOS". A presente invenção apresenta um agente preventivo ou terapêutico para o hiperlipidemia, o qual compreende, como um ingrediente ativo, um composto heterocíclico da fórmula [1], ou um seu sal farmaceuticamente aceitável: em que: R^ 1^ é arila opcionalmente substituída ou um grupo heterocíclico aromático, Het é um grupo heterocíclico aromático divalente, D é alquileno, alquenileno, alquinileno, ou um outro ainda, e E é carbóxi, ou um outro ainda, e novos compostos entre os compostos heterocíclicos da fórmula [1] acima, que tem um efeito de redução de triglicerídeo no sangue, um efeito de redução de LDL-C, um efeito de redução de glicose no sangue, um efeito de redução de insulina no sangue, ou um efeito de aumento crescente de HDL-C ou um efeito de redução do índice aterogênico todos juntos, e desse modo é útil na prevenção ou no tratamento de hiperlipidemia, arteriosclerose, diabetes melito, hipertensão, obesidade, e similares.
BR0111199-0A 2000-05-26 2001-05-25 Compostos heterocìclicos BR0111199A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000156936 2000-05-26
PCT/JP2001/004400 WO2001090087A1 (fr) 2000-05-26 2001-05-25 Composes heterocycliques

Publications (1)

Publication Number Publication Date
BR0111199A true BR0111199A (pt) 2003-04-01

Family

ID=18661643

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0111199-0A BR0111199A (pt) 2000-05-26 2001-05-25 Compostos heterocìclicos

Country Status (16)

Country Link
US (4) US7144906B2 (pt)
EP (2) EP1295875A4 (pt)
JP (1) JP3591514B2 (pt)
KR (1) KR100545507B1 (pt)
CN (1) CN1238347C (pt)
AU (2) AU2001258841B2 (pt)
BR (1) BR0111199A (pt)
CA (1) CA2410382A1 (pt)
HU (1) HUP0302397A3 (pt)
IL (1) IL152979A0 (pt)
MX (1) MXPA02011609A (pt)
NO (1) NO20025659L (pt)
RU (1) RU2259361C2 (pt)
UA (1) UA72625C2 (pt)
WO (1) WO2001090087A1 (pt)
ZA (1) ZA200209152B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2525302A1 (en) 2003-05-12 2004-11-18 David Bundle Multivalent inhibitors of serum amyloid p component
EP1479677A1 (en) * 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH New indole derivatives as factor xa inhibitors
AU2004272428A1 (en) * 2003-09-12 2005-03-24 Nippon Shinyaku Co., Ltd. Crystal of heterocyclic compound
EP1709035A1 (en) * 2004-01-09 2006-10-11 Cadila Healthcare Ltd. 1 , 3 - dioxane derivatives and analogues thereof useful in the treatment of i.a. obesity and diabetes
JP2008510696A (ja) * 2004-08-20 2008-04-10 カディラ ヘルスケア リミティド 新規抗糖尿病化合物
WO2006030892A1 (ja) * 2004-09-17 2006-03-23 Nippon Shinyaku Co., Ltd. 複素環化合物の製造方法
WO2007096261A2 (en) * 2006-02-21 2007-08-30 F. Hoffmann-La Roche Ag Process for the preparation of dioxane derivatives
RU2444518C2 (ru) * 2007-01-08 2012-03-10 Сеул Нэшнл Юниверсити Индастри Фаундейшн ПРОИЗВОДНОЕ ТИАЗОЛА КАК PPARδ ЛИГАНД И ФАРМАЦЕВТИЧЕСКИЙ, КОСМЕТИЧЕСКИЙ И ДИЕТИЧЕСКИЙ ПИЩЕВОЙ ПРОДУКТ, СОДЕРЖАЩИЙ ЕГО
JP5357894B2 (ja) 2008-12-01 2013-12-04 田辺三菱製薬株式会社 チアゾール環を含むカルボン酸誘導体およびその医薬用途
PT2427415T (pt) * 2009-05-08 2019-05-31 Basf As Ácidos gordos polinsaturados para o tratamento de doenças relacionadas com as áreas cardiovascular, metabólica e de doença inflamatória
UA104489C2 (uk) * 2009-10-01 2014-02-10 Каділа Хелткере Лімітед Сполуки для лікування дисліпідемії та споріднених хвороб
LT3573611T (lt) * 2017-01-24 2022-03-25 Alphala Co., Ltd. Amidų junginiai ir jų naudojimas

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1473212A (en) * 1974-02-27 1977-05-11 Wyeth John & Brother Ltd Thiazolylmethyl acetic acid derivatives methods for their preparation and compositions containing them
JPS60208971A (ja) * 1984-03-30 1985-10-21 Hisamitsu Pharmaceut Co Inc 新規なオキサゾ−ル誘導体
ZW19786A1 (en) * 1985-10-17 1988-05-18 Hoffmann La Roche Heterocyclic compounds
FR2699172B1 (fr) 1992-12-11 1995-01-20 Adir Nouveaux dérivés de 4-méthyl-1,3-oxazole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
US5614544A (en) * 1993-09-14 1997-03-25 Takeda Chemical Industries, Ltd. Oxazolidinedione derivatives and their use
WO1999031056A1 (fr) 1997-12-12 1999-06-24 Toyama Chemical Co., Ltd. Derives d'ether alcoylique ou leurs sels, et antagonistes du calcium les contenant
JP4345230B2 (ja) * 1998-03-10 2009-10-14 小野薬品工業株式会社 カルボン酸誘導体およびその誘導体を有効成分として含有する薬剤
US6664281B1 (en) * 1998-08-27 2003-12-16 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
US6589969B1 (en) * 1998-10-16 2003-07-08 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
GB0031109D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
GB0031107D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
KR100654516B1 (ko) * 2001-05-15 2006-12-05 에프. 호프만-라 로슈 아게 당뇨병 치료에서 ｐｐａｒ-알파 및 -감마 활성제로서사용하기 위한 카복실산 치환된 옥사졸 유도체
JP4436129B2 (ja) * 2001-08-31 2010-03-24 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ジアリールシクロアルキル誘導体、その製造法及びｐｐａｒ−活性剤としてのその使用
US6716842B2 (en) * 2002-04-05 2004-04-06 Warner-Lambert Company, Llc Antidiabetic agents

Also Published As

Publication number Publication date
US7144906B2 (en) 2006-12-05
KR100545507B1 (ko) 2006-01-24
UA72625C2 (uk) 2005-03-15
EP1634876A2 (en) 2006-03-15
NO20025659D0 (no) 2002-11-25
IL152979A0 (en) 2003-06-24
US20050009785A1 (en) 2005-01-13
ZA200209152B (en) 2004-02-11
CA2410382A1 (en) 2002-11-25
KR20030019399A (ko) 2003-03-06
HUP0302397A2 (hu) 2003-11-28
EP1295875A1 (en) 2003-03-26
AU2001258841B2 (en) 2005-06-23
CN1238347C (zh) 2006-01-25
CN1430612A (zh) 2003-07-16
HUP0302397A3 (en) 2007-02-28
RU2259361C2 (ru) 2005-08-27
NO20025659L (no) 2002-11-25
WO2001090087A1 (fr) 2001-11-29
US7022723B2 (en) 2006-04-04
MXPA02011609A (es) 2003-03-27
US7030143B2 (en) 2006-04-18
EP1634876A3 (en) 2007-03-14
AU5884101A (en) 2001-12-03
US20040162325A1 (en) 2004-08-19
US20050009892A1 (en) 2005-01-13
JP3591514B2 (ja) 2004-11-24
EP1295875A4 (en) 2004-05-06
US6998412B2 (en) 2006-02-14
US20030166697A1 (en) 2003-09-04

Similar Documents

Publication Publication Date Title
BR0111199A (pt) Compostos heterocìclicos
AU2849392A (en) Aromatic amino-alcohol derivatives having anti-diabetic and anti-obesity properties, their preparation and their therapeutic uses
WO2004087646A3 (de) Pyrrolidin -1,2-dicarbonsäure-1-(phenylamid) -2- (4-(3-oxo-morpholin-4-yl)-phenylamid) derivate und verwandte verbindungen als inhibitoren des koagulationsfaktors xa zur behandlung von thromboembolischen erkrankungen
BR9408378A (pt) Composto sal farmaceuticamente aceitável composição farmacêutica e processos para o tratamento de um paciente que sofreu um derrame e que sofre de uma condição de perda progressiva de função de sistema nervoso central e para melhorar os efeitos colaterais causados em um paciente por tratamento antineoplástico de doença que produz danos oxidativos
KR970027098A (ko) 프로피오페논 유도체 및 이의 제조 방법
BR0212078A (pt) Método de tratar ou prevenir uma doença relacionada com amilóide em um paciente, composição farmacêutica, composto quìmico, e, uso de um composto
AU3307695A (en) Oxime derivatives, their preparation and their therapeutic use
WO1999012532A3 (en) Piperidine derivatives against malaria
GR3033786T3 (en) Novel 2,3,5-trimethyl-4-hydroxy anilide derivatives, preparation thereof and therapeutical use thereof
AU4396899A (en) Remedies for diabetes
WO2002042271A3 (en) Biphenylcarboxamides useful as lipid lowering agents
BRPI0405657A (pt) Método para o tratamento de insuficiência cardìaca grave e medicamento para o mesmo
KR970059175A (ko) 벤조아진 유도체 또는 그 염 및 이를 함유하는 의약 조성물
BR0011928A (pt) Composto, composição farmacêutica, uso de, um composto e métodos para o tratamento de complicações diabéticas, para o tratamento ou a prevenção do desenvolvimento de condições de doença associadas com velocidade de condução neuronial prejudicada e de neuropatia diabética
CA2344144A1 (en) Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof
EP0974363A4 (en) REMEDIES FOR ADDICTION
ATE358128T1 (de) Vorbeugende oder therapeutische mittel gegen gastrische oder ösophageale regurgitation
BR0213237A (pt) Derivados de ácido [[2-(amino-3,4-dioxo-1-ciclobuten-1-il) amino] alquila] para o tratamento de dor
KR900012903A (ko) 피롤리딘 화합물 및 약제학적 용도
EP0978278A4 (en) ANTI-DIABETIC DRUGS
KR930701170A (ko) 항당뇨병약품
WO2001016096A3 (de) Verwendung von bissulfonamiden zur herstellung von medikamenten zur prophylaxe oder behandlung von hyperlipidämie
SE9901572D0 (sv) New compounds
NO323556B1 (no) Forbindelser, farmasoytiske preparater som omfatter forbindelsene, og anvendelse av forbindelsene ved fremstilling av antibakterielle medikamenter.
EP1130018A4 (en) DRUGS FOR DRUG ADDICTION

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 7A. E 8A. ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2008 DE 30/06/2009.